真實世界證據解決方案市場：機會、成長要素、產業趨勢分析及2026年至2035年預測

2025 年全球真實世界證據 (RWE) 解決方案市值為 26 億美元，預計到 2035 年將達到 119 億美元，複合年成長率為 16.3%。

這一強勁的成長動能源自於人們日益重視加速藥物研發進程並降低整體研發成本。醫療保健相關人員越來越重視對藥物和醫療設備的安全性和有效性進行即時監測，這進一步強化了對先進真實世界證據（RWE）平台的需求。在報銷和保險資格決策中對真實世界證據的日益依賴也促進了市場擴張。此外，先進數據分析在臨床決策流程中的廣泛應用正在改變醫療機構評估治療結果和療效的方式。隨著醫療保健系統向數據驅動型策略轉型，真實世界數據解決方案正成為支持監管申報、最佳化產品生命週期和提升患者照護品質的關鍵工具。雲端運算、人工智慧和大規模資料整合技術的持續創新正在增強RWE平台的可近性和分析能力，從而實現市場的長期持續成長。

真實世界數據 (RWE) 解決方案在現代醫療保健中發揮著至關重要的作用，它能夠分析日常臨床實踐中產生的數據。這些平台處理從電子健康記錄、理賠資料庫、患者登記資料和數位健康技術中收集的醫療資訊，為臨床、監管和商業性決策提供依據。 RWE 解決方案的應用領域十分廣泛，包括藥物研發、臨床試驗規劃、上市後安全性監測、監管文件編制以及基於價值的醫療保健項目。隨著基於價值的報銷模式的推進，對受控臨床試驗環境之外的全面結果評估的需求日益成長。醫療技術評估機構和支付方正逐步將 RWE 納入在真實世界條件下進行的治療效果評估中。分析技術和資料互通性的進步不斷改進複雜醫療資料集的整合和解讀。

預計到2025年，服務業將佔據58.4%的市場佔有率，凸顯其在全球真實世界數據解決方案市場的核心地位。服務業在真實世界數據舉措中提供研究設計、實施和法規遵循的關鍵專業知識。這些服務幫助醫療保健和生命科學機構在不同的法規環境和臨床環境中產生可操作的見解。資料聚合和管理能力尤其重要，它能夠協調多個醫療保健資料流，同時確保品管、標準化和符合當地法規。

預計到2025年，藥物研發和核准領域的市場規模將達到9.767億美元。傳統研發路徑日益複雜、高成本且風險不斷上升，促使製藥公司將真實世界證據（RWE）融入其臨床研究策略。 RWE正被用於最佳化試驗通訊協定、改善病患篩選流程，並透過真實世界數據洞察提升營運效率。此外，這些解決方案還支援在受控試驗環境之外進行長期安全性監測和療效評估。

預計到2025年，北美真實世界證據解決方案市場將佔據43.3%的佔有率，這主要得益於先進的醫療基礎設施、電子健康記錄系統的廣泛應用以及基於雲端和人工智慧的分析平台的強勁普及。慢性病的高發生率進一步推動了對持續結果監測和數據驅動型護理模式的需求。該地區的醫療服務提供者、支付者和生命科學公司正在利用真實世界證據平台來識別高風險族群、支持預防策略並評估真實世界中的治療效果。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章業界考察

• 生態系分析
• 影響產業的因素
  • 促進因素
    • 越來越重視加快藥物研發速度和降低成本。
    • 對藥品和醫療設備。
    • 擴大採用真實世界證據（RWE）解決方案進行基於資訊的還款決策
    • 擴巨量資料分析服務在臨床決策中的應用
  • 產業潛在風險與挑戰：
    • 現實世界數據的整合和互通性缺乏標準化
    • 熟練專業人員短缺
  • 市場機遇
    • 癌症以外的新興治療領域拓展
    • 專注於整合患者產生的健康數據
• 成長潛力分析
• 監理情勢
• 技術進步
  • 當前技術趨勢
  • 新興技術
• 未來市場趨勢
• 波特五力分析
• PESTEL 分析

第4章 競爭情勢

• 介紹
• 企業市佔率分析
• 公司矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 合作夥伴關係和合資企業
  • 新產品發布
  • 擴張計劃

第5章 市場估計與預測：依組件分類，2022-2035年

• 服務
  • CD/整合
  • 研究設計與實施
    • 前瞻性觀察研究
    • 回顧性資料庫研究
    • 以地點為中心的研究
    • 基於註冊登記的研究
    • 混合研究
  • 監管和市場進入支持
  • 證據網路
  • 其他服務
• 資料集
  • 異質資料集
    • 臨床實踐資料集
    • 發票資料集
    • 藥房資料集
    • 患者主導的資料集
    • 基於註冊表的資料集
  • 綜合資料集

第6章 市場估計與預測：依應用領域分類，2022-2035年

• 藥物研發及核准
  • 腫瘤學
  • 循環系統疾病
  • 神經病學
  • 免疫學
  • 其他治療領域
• 醫療設備的研發與核准
• 上市後監測
• 市場進入與報銷/保險範圍決策
• 臨床和監管決策

第7章 市場估計與預測：依所得模式分類，2022-2035年

• 計量收費（按價值定價）
• 訂閱

第8章 市場估算與預測：依部署模式分類，2022-2035年

• 現場
• 基於雲端的

第9章 市場估計與預測：依最終用途分類，2022-2035年

• 製藥公司和醫療設備製造商
• 健康保險提供者
• 醫療保健提供者
• 其他最終用戶

第10章 市場估價與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國

第11章：公司簡介

• Aetion, Inc.
• Cytel Inc
• Flatiron Health Inc
• Fortrea Holdings Inc
• IBM Corporation
• ICON plc
• IQVIA Holdings Inc.
• Medidata Solutions, Inc.
• Merative
• Oracle Corporation
• Parexel International Corporation
• Syneos Health Inc
• Tempus
• TriNetX
• Thermo Fisher Scientific, Inc

The Global Real World Evidence Solutions Market was valued at USD 2.6 billion in 2025 and is estimated to grow at a CAGR of 16.3% to reach USD 11.9 billion by 2035.

The robust growth trajectory is fueled by the increasing emphasis on accelerating drug development timelines while reducing overall research costs. Healthcare stakeholders are placing greater importance on real-time monitoring of drug and medical device safety and effectiveness, further strengthening demand for advanced RWE platforms. Growing reliance on real world evidence for reimbursement and coverage decisions is also contributing to market expansion. In addition, the broader adoption of advanced data analytics in clinical decision-making processes is transforming how healthcare organizations evaluate outcomes and treatment value. As healthcare systems shift toward data-driven strategies, real world evidence solutions are becoming essential tools for supporting regulatory submissions, optimizing product lifecycles, and improving patient care quality. Continuous innovation in cloud computing, artificial intelligence, and large-scale data integration technologies is enhancing the accessibility and analytical power of RWE platforms, positioning the market for sustained long-term growth.

Real world evidence solutions serve a critical function in modern healthcare by enabling the analysis of data generated during routine clinical practice. These platforms process healthcare information collected from electronic health records, claims databases, patient registries, and digital health technologies to inform clinical, regulatory, and commercial decisions. RWE solutions are widely applied across drug development, clinical trial planning, post-market safety monitoring, regulatory documentation, and value-based care programs. The ongoing transition toward value-based reimbursement models is increasing the need for comprehensive outcome assessments beyond controlled clinical trial environments. Health technology assessment bodies and payers are progressively incorporating RWE into therapy performance evaluations conducted under real-world conditions. Advancements in analytics and data interoperability continue to improve the integration and interpretation of complex healthcare datasets.

The services segment accounted for 58.4% share in 2025, highlighting its central role within the global real world evidence solutions market. Service offerings provide essential expertise in study design, execution, and regulatory alignment for RWE initiatives. These services support healthcare and life sciences organizations in generating actionable insights across diverse regulatory and clinical settings. Data aggregation and management capabilities are particularly critical, as they enable the harmonization of multiple healthcare data streams while ensuring quality control, standardization, and compliance with regional regulations.

The drug development and approvals segment generated USD 976.7 million in 2025. Increasing complexity, high costs, and elevated risks associated with traditional development pathways are encouraging pharmaceutical companies to integrate real world evidence into clinical research strategies. RWE is being used to refine trial protocols, enhance patient selection processes, and improve operational efficiency through real-world data insights. Additionally, these solutions support long-term safety surveillance and effectiveness assessments beyond controlled trial settings.

North America Real World Evidence Solutions Market held 43.3% share in 2025, supported by advanced healthcare infrastructure, widespread implementation of electronic health record systems, and strong adoption of cloud-based and AI-enabled analytics platforms. High prevalence of chronic diseases further increases demand for continuous outcome monitoring and data-driven care models. Healthcare providers, payers, and life sciences companies in the region leverage RWE platforms to identify high-risk populations, support preventive strategies, and evaluate real-world treatment performance.

Prominent companies operating in the Global Real World Evidence Solutions Market include Aetion, Inc., Cytel Inc, Flatiron Health Inc, Fortrea Holdings Inc, IBM Corporation, ICON plc, IQVIA Holdings Inc., Medidata Solutions, Inc., Merative, Oracle Corporation, Parexel International Corporation, Syneos Health Inc, Tempus, TriNetX, Thermo Fisher Scientific, Inc, and UnitedHealth Group Incorporated. Companies competing in the Global Real World Evidence Solutions Market are strengthening their market presence through strategic collaborations, technology integration, and expansion of analytics capabilities. Leading players are investing in advanced artificial intelligence and machine learning platforms to enhance predictive insights and real-time data interpretation. Partnerships with healthcare providers, payers, and pharmaceutical firms are enabling broader access to diverse datasets. Firms are also prioritizing regulatory compliance expertise to support global study submissions. Cloud-based infrastructure development and scalable data platforms are improving interoperability and client accessibility.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Component trends
  • 2.2.3 Application trends
  • 2.2.4 Revenue model trends
  • 2.2.5 Deployment model trends
  • 2.2.6 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing focus towards accelerating drug development and cost reduction
    • 3.2.1.2 Growing demand for real-time safety and efficacy monitoring of drugs and medical devices
    • 3.2.1.3 Increasing adoption of RWE solutions for informed reimbursement decision-making
    • 3.2.1.4 Increasing adoption of data analytics services in clinical decision making.
  • 3.2.2 Industry Pitfalls and Challenges:
    • 3.2.2.1 Lack of standardization in integration and interoperability of real-world data
    • 3.2.2.2 Shortage of skilled professionals
  • 3.2.3 Market Opportunities
    • 3.2.3.1 Emerging therapeutic areas expansion beyond oncology
    • 3.2.3.2 Focus on patient-generated health data integration
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological advancements
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Component, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Services
  • 5.2.1 Data collection and integration
  • 5.2.2 Study design and execution
    • 5.2.2.1 Prospective observational studies
    • 5.2.2.2 Retrospective database studies
    • 5.2.2.3 Site-centric studies
    • 5.2.2.4 Registry-based studies
    • 5.2.2.5 Hybrid studies
  • 5.2.3 Regulatory and market access support
  • 5.2.4 Evidence network
  • 5.2.5 Other services
• 5.3 Data sets
  • 5.3.1 Disparate data sets
    • 5.3.1.1 Clinical settings data sets
    • 5.3.1.2 Claims data sets
    • 5.3.1.3 Pharmacy data sets
    • 5.3.1.4 Patient powered data sets
    • 5.3.1.5 Registry-based data sets
  • 5.3.2 Integrated data sets

Chapter 6 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Drug development and approvals
  • 6.2.1 Oncology
  • 6.2.2 Cardiovascular disease
  • 6.2.3 Neurology
  • 6.2.4 Immunology
  • 6.2.5 Other therapeutic areas
• 6.3 Medical device development and approvals
• 6.4 Post-market surveillance
• 6.5 Market access and reimbursement/coverage decision-making
• 6.6 Clinical and regulatory decision-making

Chapter 7 Market Estimates and Forecast, By Revenue Model, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Pay-per-use (value-based pricing)
• 7.3 Subscription

Chapter 8 Market Estimates and Forecast, By Deployment Model, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 On-premise
• 8.3 Cloud-based

Chapter 9 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 Pharmaceutical and medical device companies
• 9.3 Healthcare payers
• 9.4 Healthcare providers
• 9.5 Other end users

Chapter 10 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 India
  • 10.4.3 Japan
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Aetion, Inc.
• 11.2 Cytel Inc
• 11.3 Flatiron Health Inc
• 11.4 Fortrea Holdings Inc
• 11.5 IBM Corporation
• 11.6 ICON plc
• 11.7 IQVIA Holdings Inc.
• 11.8 Medidata Solutions, Inc.
• 11.9 Merative
• 11.10 Oracle Corporation
• 11.11 Parexel International Corporation
• 11.12 Syneos Health Inc
• 11.13 Tempus
• 11.14 TriNetX
• 11.15 Thermo Fisher Scientific, Inc